AOD-9604: clinical history and the modern peptide market

AOD-9604 sits in a strange spot in the strength-peptide market. It is widely sold as a "fat-loss peptide," advertised as a clean alternative to growth hormone, and routinely stacked into recomp protocols. It is also a compound that completed multiple human trials for obesity, was discontinued for that indication, and was repositioned for entirely different uses. That history is rarely mentioned in the marketing. It should be — because it changes how you should think about the case for using AOD-9604 as a body-composition tool.

What AOD-9604 actually is

AOD-9604 is a 16-amino-acid synthetic peptide based on the C-terminal end of human growth hormone (residues 176–191), with an additional N-terminal tyrosine added to improve oral and analytical stability. The original premise: this region of the GH molecule was theorized to carry the lipolytic — fat-burning — activity of full GH, while the IGF-1, glucose-disrupting, and proliferative effects were thought to live elsewhere on the molecule.

If that premise held, AOD-9604 would be a genuinely useful drug — a fat-loss agent that didn't drag along the side-effect profile that limits real GH for recomposition. Metabolic Pharmaceuticals (Australia) saw the same opportunity and built a development program around it.

The clinical history

Metabolic Pharmaceuticals took AOD-9604 through multiple trials in the 2000s. The high-level picture, from publicly available trial summaries and regulatory filings:

• Phase 1 dose-finding studies demonstrated the peptide was safe and well-tolerated at doses up to 1 mg/day. Lipolytic markers responded modestly.
• Phase 2a obesity studies (12-week trials in obese adults) showed lipolytic activity but did not meet the weight-loss endpoint at clinically meaningful magnitudes.
• Phase 2b extended studies failed to demonstrate weight loss greater than placebo.
• The obesity development program was eventually wound down. AOD-9604 was repositioned for osteoarthritis and cartilage repair, which had different — though also unconvincing — clinical results.

The honest summary: across the most rigorous trials AOD-9604 ever ran, the compound was safe but did not produce meaningful fat loss versus placebo. The mechanism was real; the clinical effect size was small; the cost-benefit case for an obesity indication did not hold up.

That's a different story from the one the peptide market tells.

How the peptide market handled the failure

Most drugs that fail late-stage trials disappear from the conversation. AOD-9604 did not. Several things happened:

Repositioning as a wellness peptide. When obesity development ended, AOD-9604 transitioned into the gray-market peptide channel. It was rebranded as a fat-loss adjunct, an anti-aging tool, and a cartilage support compound. None of those framings depend on the failed obesity trials, so the marketing simply did not reference them.

Repackaging at lower doses. Trial doses were higher than research-chemical-channel doses. That's normal — wellness-tier peptide protocols generally undershoot trial doses to limit side effects. But it also means the doses being used today are below the levels that already failed to beat placebo in trials.

Conflation with HGH fragment 176-191. AOD-9604 is a modified version of 176-191. The two are sometimes sold interchangeably, sometimes labeled identically, and sometimes priced very differently. Vendors with rigorous third-party Certificates of Analysis can usually clarify which compound is in the vial. Vendors without COAs cannot. See reading a COA: worked example.

What users actually report

In long-form community feedback over years of AOD-9604 use, the consistent pattern is:

• Modest scale movement (1–3 lb fat loss over 8–12 weeks) on top of an aggressive cut
• No notable IGF-1 spike or fasting-glucose shift, matching the mechanistic claim
• No appetite suppression — this is not a GLP-1 mimetic
• Generally well-tolerated; minimal injection-site issues
• Hard to attribute reliably without controlled measurement

The mechanism appears to do something. The effect is small enough that you cannot distinguish AOD-9604's contribution from diet, training, water-weight changes, and placebo without measured baselines and tight control.

How AOD-9604 compares to alternatives

If you're choosing between AOD-9604 and tesamorelin specifically for visceral-fat reduction, tesamorelin has actual FDA-approval-level data. See tesamorelin: visceral fat literature and tesamorelin: real-world reports.

Where AOD-9604 still might fit

There are reasonable cases for running it:

• A late-stage cut where you want a non-GH-side-effect adjunct — small effect, low side-effect cost, may help at the margin
• Stacked with cardio and nutrition adherence — not as a replacement
• Users who specifically cannot tolerate GH secretagogues because of joint pain, water retention, or fasting-glucose issues — AOD-9604's clean profile is a real advantage there

Cases where the math doesn't work:

• As a primary fat-loss tool when GLP-1 agonists, structured nutrition, or tesamorelin (for the right indication) are available
• For users without a baseline cut already in motion — you cannot lipolyze fat that isn't being mobilized by an energy deficit
• For users who can't reliably source and verify the compound — see is your peptide vendor legit

The bigger lesson

AOD-9604's history is a useful case study in how the peptide market metabolizes drug-development failures. A compound runs trials, fails its endpoints, exits the regulated pathway, and then gets repackaged for adjacent uses where the failure isn't directly relevant. The marketing language shifts from "weight loss" to "body composition support" or "lipolytic peptide." The original trial data, which is the most rigorous evidence anyone has on the molecule, gets buried.

That doesn't mean every repurposed peptide is a fraud — some genuinely do find legitimate adjacent uses. It does mean that "this peptide is sold for fat loss" and "this peptide produces meaningful fat loss in human trials" are two very different claims, and the second one carries the weight you actually want before adding a compound to your protocol.

For AOD-9604 specifically: it is well-tolerated, mechanistically real, and clinically modest. If you run it, run it knowing the size of the effect the trials actually measured.

Related reading

• Cutting with peptides: what works
• Tesamorelin: visceral fat literature
• Tesamorelin: real-world reports
• Reading a COA: worked example
• GH secretagogues pillar